King Faisal Specialist Hospital and Research Centre Highlights its Space Biomedical Research Journey at the Global Health Exhibition
RIYADH, Saudi Arabia, Oct. 29, 2023 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH&RC) is presenting its pioneering journey and prospects in space biomedical research and its role in enhancing human health at the Global Health Exhibition, where KFSH&RC is also participating as a strategic healthcare partner.
At the Exhibition, KFSH&RC delves into its groundbreaking experience leading four research experiments in cell sciences in space. These experiments encompass testing the immune cell response to inflammation in space, monitoring the activity of thousands of genes in immune cells exposed to inflammation over time, and tracking the changes in the lifespan of ribonucleic acid (mRNA) between space and Earth. Additionally, the pavilion simulates the inflammatory response to drug treatment using an immune cell model to explore its potential applications for prevention and early treatment.
The aim of these research experiments, conducted in collaboration with the Saudi Space Authority, as part of the scientific mission of Saudi astronauts Rayyanah Barnawi and Ali Al-Qarni to the International Space Station (ISS), is to contribute to exploratory research and its applications in space medicine to enhance the safety of space explorers and utilize the knowledge gained for the benefit the patient community globally.
The scientific experiments lasted for four days and were overseen by the research team led by Dr. Khaled Saad Abu Khubrah, Head of the Department of Molecular Biomedicine and Research at KFSH&RC, along with Dr. Wijdan Al-Ahmadi from KFSH&RC and Dr. Edward Hattie from the BioServe Space Technologies Center in Colorado, USA.
KFSH&RC is actively pursuing further research in space biomedical science to gain a more comprehensive understanding of the effects of gravity deficiency and cosmic radiation on the human body. They aim to leverage the unique space environment, which provides opportunities for medical experiments that are not feasible on Earth. This includes studying how cells and tissues grow in microgravity conditions, potentially leading to groundbreaking discoveries in disease treatments and opening new avenues in space medicine.
KFSH&RC is globally renowned for its specialized healthcare services and its leadership in innovation. It stands as an advanced centre for medical research and education, aiming to advance medical technologies and raise the standard of healthcare worldwide through partnerships with prominent local, regional, and international institutions in clinical, research, and educational fields.
Contact information:
kfshrc@mcsaatchi.com
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/78eba5fa-19d6-437c-ab42-c9a09636e91e
https://www.globenewswire.com/NewsRoom/AttachmentNg/c30c198b-dd13-4d48-8b8c-6667eda49b45
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Buy-backs of shares in CoinShares International Limited29.11.2023 09:00:00 CET | Press release
29 November 2023 | SAINT HELIER, Jersey - As announced on 07 November 2023, the Board of Directors of CoinShares International Limited ("CoinShares" or the "Company") (Nasdaq Stockholm Market: CS; US OTCQX: CNSRF), Europe's leading alternative asset manager specialising in digital assets, resolved to extend a share buy-back program and repurchase shares on Nasdaq Stockholm Market during the period 07 November 2023, up to and including 30 May 2024 for total maximum amount of SEK 30 million in accordance with the authorisation from the Annual General Meeting on 31 May 2023. The Board of Directors’ resolution to implement the share buy-back program was made after the Board's review of the Company's capital structure and was implemented for the purposes of reducing the capital of the Company. The share buy-back program is carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 ("MAR") and the Commission Delegated Regulation (EU) No 2016/1052 (the "Safe Harbour Regulatio
Deutsche Digital Assets Wins Pension Fund as Anchor Investor for DDA Crypto Select 10 ETP (SLCT)29.11.2023 09:00:00 CET | Press release
Institutional anchor investor for DDA Crypto Select 10 ETP (ISIN: DE000A3G3ZD0; WKN: A3G3ZD, Ticker: SLCT) The DDA Crypto Select 10 ETP reflects the MarketVector™ Digital Assets Max 10 VWAP Close Index (“MVDAMV”)With the ETP, investors are in a position to affordably gain exposure to a basket collection of (up to) the 10 most important crypto assetsThe ETP is 100% collateralized by coins held in an institutional custody solution FRANKFURT, Germany, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Deutsche Digital Assets GmbH has gained a renowned institutional anchor investor for the DDA Crypto Select 10 ETP (ISIN: DE000A3G3ZD0 | WKN: A3G3ZD), which was launched in June 2023. DDA prevailed against the competition in a selection process and was commissioned to design a crypto ETP that meets high quality standards and strict requirements of an institutional investor. After several months of preparation, this investment product can now be administered by a leading capital management company acting on be
Yara helps farmers combat the effects of climate change and improve nutrient use efficiency29.11.2023 08:40:00 CET | Press release
Global rise in temperatures has introduced a challenging reality for farmers worldwide. To meet the increasing demand for solutions to protect crops against climate change and optimize nutrient use efficiency, Yara is launching YaraAmplix™. A new brand that will expand the range of biostimulants. November 29th 2023 Milan: Climate change is putting many of the world’s most popular foods such as maize, tomato and wheat at risk of reduced crops. With the average global temperature on earth having already increased by over 1 degree Celsius in the last 100 years*1, agriculture is now experiencing more extreme weather than ever before with temperature increases being most severe on land. In response to farmers asking for solutions to increase crop resilience and nutrient use efficiency, Yara today announces the launch of YaraAmplix, a new brand of biostimulants, at the Biostimulant World Congress in Milan, Italy. “Extreme weather is destroying crops all over the world with drought, flooding
Sanoma Corporation - Managers' Transactions29.11.2023 08:30:00 CET | Press release
Sanoma Corporation, Managers’ Transactions, 29 November 2023 at 9:30 EET Sanoma Corporation - Managers' Transactions ___________________________________________ Person subject to the notification requirement Name: Holding Manutas Oy Position: Closely associated person (X) Legal person (1):Person Discharging Managerial Responsibilities In Issuer Name: Herlin Anna Position: Member of the Board Issuer: Sanoma Oyj LEI: 743700XJC24THUPK0S03 Notification type: INITIAL NOTIFICATION Reference number: 44711/8/10 ____________________________________________ Transaction date: 2023-11-28 Venue: AQEU Instrument type: SHARE ISIN: FI0009007694 Nature of transaction: ACQUISITION Transaction details (1): Volume: 250 Unit price: 6.87 EUR (2): Volume: 32 Unit price: 6.9 EUR Aggregated transactions (2): Volume: 282 Volume weighted average price: 6.8734 EUR ____________________________________________ Transaction date: 2023-11-28 Venue: BEUP Instrument type: SHARE ISIN: FI0009007694 Nature of transaction:
Delårsrapport for 1. januar - 30. september 2023 for FirstFarms A/S29.11.2023 08:05:40 CET | pressemeddelelse
FirstFarms leverer tilfredstillende i udfordrende marked FirstFarms skaber fornuftige resultater på trods af høj inflation på omkostninger og stort pres på salgspriser. Omsætningsfremgang på 19% og fastholdelse af udmeldte forventninger til året. Bestyrelsen og direktionen i FirstFarms A/S har d.d. behandlet og godkendt det ureviderede delårsregnskab for perioden 1. januar - 30. september 2023. FirstFarms har i regnskabsperioden realiseret: Omsætning: 345 mDKK (2022: 291 mDKK)EBITDA: 79 mDKK (2022: 121 mDKK)EBIT: 42 mDKK (2022: 89 mDKK)Resultat før skat: 28 mDKK (2022: 77 mDKK) Produktion og resultatskabelse er tilfredsstillende med baggrund i de udfordrende forudsætninger FirstFarms har opereret under i årets første tre kvartaler. Resultatet er skabt som følge af en stabil, effektiv, cirkulær drift samt den risikospredning, der er et positivt og væsentligt særkende for koncernen. FirstFarms A/S fastholder derfor de udmeldte forventninger for 2023. Dog med et EBITDA i den nedre del af